Damora Therapeutics (DMRA) Net Equity Issued and Repurchased (2020 - 2023)
Damora Therapeutics' (DMRA) quarterly Net Equity Issued and Repurchased came in at $171000.0 in Q3 2023, down 59.67% YoY from $424000.0 in Q3 2022, and down 93.62% on a QoQ basis from $2.7 million in Q2 2023.
Damora Therapeutics (DMRA) Net Equity Issued and Repurchased (2020 - 2023) Analysis & Trends
Damora Therapeutics (DMRA) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $171000.0 in Q3 2023.
- Quarterly Net Equity Issued and Repurchased fell 59.67% year-over-year to $171000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $2.9 million (up 488.14% YoY) and the FY2023 annual result came in at $2.9 million, up 467.26% from the prior year.
- Net Equity Issued and Repurchased eased to $171000.0 in Q3 2023, from $2.7 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $39.7 million in Q1 2020 to a low of -$19.1 million in Q4 2020.
- A 3-year average of $4.8 million and a median of $171000.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 59.67% in 2023, down 59.67% in 2023.
- Tracing DMRA's Net Equity Issued and Repurchased over 3 years: stood at -$19.1 million in 2020, then soared by 100.34% to $65000.0 in 2022, then jumped by 163.08% to $171000.0 in 2023.
- The last three Net Equity Issued and Repurchased figures came in at $171000.0 (Q3 2023), $2.7 million (Q2 2023), and $23000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 171,000.00 |
| Sep 30, 2023 | 171,000.00 |
| Jun 30, 2023 | 2.68 Mn |
| Jun 30, 2023 | 2.68 Mn |
| Mar 31, 2023 | 23,000.00 |
| Mar 31, 2023 | 23,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Sep 30, 2022 | 424,000.00 |
| Sep 30, 2022 | 424,000.00 |
| Dec 31, 2020 | -19.06 Mn |
| Dec 31, 2020 | -19.06 Mn |
| Sep 30, 2020 | 19.06 Mn |
| Sep 30, 2020 | 19.06 Mn |
| Jun 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Mar 31, 2020 | 39.67 Mn |
| Mar 31, 2020 | 39.67 Mn |